JAMA Internal Medicine最新文献

筛选
英文 中文
Errors in the Number of Eligible Bars/Taverns in Study of Closing Hours and Violent Crime. 打烊时间与暴力犯罪研究中合格酒吧/酒馆数量的误差。
IF 22.5 1区 医学
JAMA Internal Medicine Pub Date : 2024-09-03 DOI: 10.1001/jamainternmed.2024.4628
Erika M Rosen
{"title":"Errors in the Number of Eligible Bars/Taverns in Study of Closing Hours and Violent Crime.","authors":"Erika M Rosen","doi":"10.1001/jamainternmed.2024.4628","DOIUrl":"https://doi.org/10.1001/jamainternmed.2024.4628","url":null,"abstract":"","PeriodicalId":14714,"journal":{"name":"JAMA Internal Medicine","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Making Financial Assistance Programs Equitable and Accessible. 使财政援助计划公平合理。
IF 22.5 1区 医学
JAMA Internal Medicine Pub Date : 2024-09-03 DOI: 10.1001/jamainternmed.2024.3561
Maanasa Kona
{"title":"Making Financial Assistance Programs Equitable and Accessible.","authors":"Maanasa Kona","doi":"10.1001/jamainternmed.2024.3561","DOIUrl":"https://doi.org/10.1001/jamainternmed.2024.3561","url":null,"abstract":"","PeriodicalId":14714,"journal":{"name":"JAMA Internal Medicine","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials. 塞马鲁肽对无已知重大精神病理学的体重控制患者的精神安全性:对 STEP 1、2、3 和 5 试验的事后分析。
IF 22.5 1区 医学
JAMA Internal Medicine Pub Date : 2024-09-03 DOI: 10.1001/jamainternmed.2024.4346
Thomas A Wadden, Gregory K Brown, Christina Egebjerg, Ofir Frenkel, Bryan Goldman, Robert F Kushner, Barbara McGowan, Maria Overvad, Anders Fink-Jensen
{"title":"Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.","authors":"Thomas A Wadden, Gregory K Brown, Christina Egebjerg, Ofir Frenkel, Bryan Goldman, Robert F Kushner, Barbara McGowan, Maria Overvad, Anders Fink-Jensen","doi":"10.1001/jamainternmed.2024.4346","DOIUrl":"10.1001/jamainternmed.2024.4346","url":null,"abstract":"<p><strong>Importance: </strong>Obesity is associated with numerous psychosocial complications, making psychiatric safety a consideration for treating people with obesity. Few studies have investigated the psychiatric safety of newly available antiobesity medications.</p><p><strong>Objective: </strong>To evaluate the psychiatric safety of subcutaneous semaglutide, 2.4 mg, once weekly in people without known major psychopathology.</p><p><strong>Design, setting, and participants: </strong>This post hoc analysis of pooled data from the randomized, double-blind, placebo-controlled, multicenter phase 3a STEP 1, 2, and 3 trials (68 weeks; 2018-2020) and phase 3b STEP 5 trial (104 weeks; 2018-2021) included adults with overweight or obesity; STEP 2 participants also had type 2 diabetes. Trial designs have been published previously.</p><p><strong>Interventions: </strong>Semaglutide, 2.4 mg, vs placebo.</p><p><strong>Main outcomes and measures: </strong>Depressive symptoms and suicidal ideation/behavior were assessed using the Patient Health Questionnaire (PHQ-9) and Columbia-Suicide Severity Rating Scale, respectively. Psychiatric and nervous system disorder adverse events were investigated.</p><p><strong>Results: </strong>This analysis included 3377 participants in the STEP 1, 2, and 3 trials (2360 women [69.6%]; mean [SD] age, 49 [13] years) and 304 participants in STEP 5 (236 women [77.6%]; mean [SD] age, 47 [11] years). In the STEP 1, 2, and 3 trials, mean (SD) baseline PHQ-9 scores for the semaglutide, 2.4 mg, and placebo groups were 2.0 (2.3) and 1.8 (2.3), respectively, indicating no/minimal symptoms of depression. PHQ-9 scores at week 68 were 2.0 (2.9) and 2.4 (3.3), respectively; the estimated treatment difference (95% CI) between groups was -0.56 (-0.81 to -0.32) (P < .001). Participants treated with semaglutide vs placebo were less likely to shift (from baseline to week 68) to a more severe category of PHQ-9 depression (odds ratio, 0.63; 95% CI, 0.50-0.79; P < .001). Based on the Columbia-Suicide Severity Rating Scale, 1% or fewer of participants reported suicidal ideation/behavior during treatment, with no differences between semaglutide, 2.4 mg, and placebo. Psychiatric disorder adverse events were generally balanced between groups. Similar results were observed in STEP 5.</p><p><strong>Conclusions and relevance: </strong>The results of this post hoc analysis suggest that treatment with semaglutide, 2.4 mg, did not increase the risk of developing symptoms of depression or suicidal ideation/behavior vs placebo and was associated with a small but statistically significant reduction in depressive symptoms (not considered clinically meaningful). People with obesity should be monitored for mental health concerns so they can receive appropriate support and care.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifiers: STEP 1 (NCT03548935), 2 (NCT03552757), 3 (NCT03611582), and 5 (NCT03693430).</p>","PeriodicalId":14714,"journal":{"name":"JAMA Internal Medicine","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 更正。
IF 22.5 1区 医学
JAMA Internal Medicine Pub Date : 2024-09-03 DOI: 10.1001/jamainternmed.2024.4676
{"title":"Correction.","authors":"","doi":"10.1001/jamainternmed.2024.4676","DOIUrl":"10.1001/jamainternmed.2024.4676","url":null,"abstract":"","PeriodicalId":14714,"journal":{"name":"JAMA Internal Medicine","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Errors in Results Section and Figure 3. 结果部分和图 3 中的错误。
IF 22.5 1区 医学
JAMA Internal Medicine Pub Date : 2024-09-03 DOI: 10.1001/jamainternmed.2024.4669
{"title":"Errors in Results Section and Figure 3.","authors":"","doi":"10.1001/jamainternmed.2024.4669","DOIUrl":"10.1001/jamainternmed.2024.4669","url":null,"abstract":"","PeriodicalId":14714,"journal":{"name":"JAMA Internal Medicine","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Screening Mammography for 40-Year-Old Women-Whose Decision? 40 岁女性的乳腺筛查--谁的决定?
IF 22.5 1区 医学
JAMA Internal Medicine Pub Date : 2024-09-03 DOI: 10.1001/jamainternmed.2024.4277
Karla Kerlikowske, Laura Esserman, Jeffrey A Tice
{"title":"Screening Mammography for 40-Year-Old Women-Whose Decision?","authors":"Karla Kerlikowske, Laura Esserman, Jeffrey A Tice","doi":"10.1001/jamainternmed.2024.4277","DOIUrl":"https://doi.org/10.1001/jamainternmed.2024.4277","url":null,"abstract":"","PeriodicalId":14714,"journal":{"name":"JAMA Internal Medicine","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying and Measuring Administrative Harms Experienced by Hospitalists and Administrative Leaders. 识别和衡量住院医生和行政领导所经历的行政伤害。
IF 22.5 1区 医学
JAMA Internal Medicine Pub Date : 2024-09-01 DOI: 10.1001/jamainternmed.2024.1890
Marisha Burden, Gopi Astik, Andrew Auerbach, Greg Bowling, Kirsten N Kangelaris, Angela Keniston, Aveena Kochar, Luci K Leykum, Anne S Linker, Matthew Sakumoto, Kendall Rogers, Natalie Schwatka, Sara Westergaard
{"title":"Identifying and Measuring Administrative Harms Experienced by Hospitalists and Administrative Leaders.","authors":"Marisha Burden, Gopi Astik, Andrew Auerbach, Greg Bowling, Kirsten N Kangelaris, Angela Keniston, Aveena Kochar, Luci K Leykum, Anne S Linker, Matthew Sakumoto, Kendall Rogers, Natalie Schwatka, Sara Westergaard","doi":"10.1001/jamainternmed.2024.1890","DOIUrl":"10.1001/jamainternmed.2024.1890","url":null,"abstract":"<p><strong>Importance: </strong>Administrative harm (AH), defined as the adverse consequences of administrative decisions within health care that impact work structure, processes, and programs, is pervasive in medicine, yet poorly understood and described.</p><p><strong>Objective: </strong>To explore common AHs experienced by hospitalist clinicians and administrative leaders, understand the challenges that exist in identifying and measuring AH, and identify potential approaches to mitigate AH.</p><p><strong>Design, setting, and participants: </strong>A qualitative study using a mixed-methods approach with a 12-question survey and semistructured virtual focus groups was held on June 13 and August 11, 2023. Rapid qualitative methods including templated summaries and matrix analysis were applied. The participants included 2 consortiums comprising hospitalist clinicians, researchers, administrative leaders, and members of a patient and family advisory council.</p><p><strong>Main outcomes and measures: </strong>Quantitative data from the survey on specific aspects of experiences related to AH were collected. Focus groups were conducted using a semistructured focus group guide. Themes and subthemes were identified.</p><p><strong>Results: </strong>Forty-one individuals from 32 different organizations participated in the focus groups, with 32 participants (78%) responding to a brief survey. Survey participants included physicians (91%), administrative professionals (6%), an advanced practice clinician (3%), and those in leadership roles (44%), with participants able to select more than one role. Only 6% of participants were familiar with the term administrative harm to a great extent, 100% felt that collaboration between administrators and clinicians is crucial for reducing AH, and 81% had personally participated in a decision that led to AH to some degree. Three main themes were identified: (1) AH is pervasive and comes from all levels of leadership, and the phenomenon was felt to be widespread and arose from multiple sources within health care systems; (2) organizations lack mechanisms for identification, measurement, and feedback, and these challenges stem from a lack of psychological safety, workplace cultures, and ambiguity in who owns a decision; and (3) organizational pressures were recognized as contributors to AHs. Many ideas were proposed as solutions.</p><p><strong>Conclusions and relevance: </strong>The findings of this study suggest that AH is widespread with wide-reaching impact, yet organizations do not have mechanisms to identify or address it.</p>","PeriodicalId":14714,"journal":{"name":"JAMA Internal Medicine","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11197021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. 塞马鲁肽与替氮帕肽用于超重或肥胖成人的减肥治疗。
IF 22.5 1区 医学
JAMA Internal Medicine Pub Date : 2024-09-01 DOI: 10.1001/jamainternmed.2024.2525
Patricia J Rodriguez, Brianna M Goodwin Cartwright, Samuel Gratzl, Rajdeep Brar, Charlotte Baker, Ty J Gluckman, Nicholas L Stucky
{"title":"Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.","authors":"Patricia J Rodriguez, Brianna M Goodwin Cartwright, Samuel Gratzl, Rajdeep Brar, Charlotte Baker, Ty J Gluckman, Nicholas L Stucky","doi":"10.1001/jamainternmed.2024.2525","DOIUrl":"10.1001/jamainternmed.2024.2525","url":null,"abstract":"<p><strong>Importance: </strong>Although tirzepatide and semaglutide were shown to reduce weight in randomized clinical trials, data from head-to-head comparisons in populations with overweight or obesity are not yet available.</p><p><strong>Objective: </strong>To compare on-treatment weight loss and rates of gastrointestinal adverse events (AEs) among adults with overweight or obesity receiving tirzepatide or semaglutide labeled for type 2 diabetes (T2D) in a clinical setting.</p><p><strong>Design, setting, and participants: </strong>In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data linked to dispensing information from a collective of US health care systems. On-treatment weight outcomes through November 3, 2023, were assessed. Adults with overweight or obesity and regular care in the year before initiation, no prior glucagon-like peptide 1 receptor agonist receptor agonist use, a prescription within 60 days prior to initiation, and an available baseline weight were identified. The analysis was completed on April 3, 2024.</p><p><strong>Exposures: </strong>Tirzepatide or semaglutide in formulations labeled for T2D, on or off label.</p><p><strong>Main outcomes and measures: </strong>On-treatment weight change in a propensity score-matched population, assessed as hazard of achieving 5% or greater, 10% or greater, and 15% or greater weight loss, and percentage change in weight at 3, 6, and 12 months. Hazards of gastrointestinal AEs were compared.</p><p><strong>Results: </strong>Among 41 222 adults meeting the study criteria (semaglutide, 32 029; tirzepatide, 9193), 18 386 remained after propensity score matching. The mean (SD) age was 52.0 (12.9) years, 12 970 were female (70.5%), 14 182 were white (77.1%), 2171 Black (11.8%), 354 Asian (1.9%), 1679 were of other or unknown race, and 9563 (52.0%) had T2D. The mean (SD) baseline weight was 110 (25.8) kg. Follow-up was ended by discontinuation for 5140 patients (55.9%) receiving tirzepatide and 4823 (52.5%) receiving semaglutide. Patients receiving tirzepatide were significantly more likely to achieve weight loss (≥5%; hazard ratio [HR], 1.76, 95% CI, 1.68, 1.84; ≥10%; HR, 2.54; 95% CI, 2.37, 2.73; and ≥15%; HR, 3.24; 95% CI, 2.91, 3.61). On-treatment changes in weight were larger for patients receiving tirzepatide at 3 months (difference, -2.4%; 95% CI -2.5% to -2.2%), 6 months (difference, -4.3%; 95% CI, -4.7% to -4.0%), and 12 months (difference, -6.9%; 95% CI, -7.9% to -5.8%). Rates of gastrointestinal AEs were similar between groups.</p><p><strong>Conclusions and relevance: </strong>In this population of adults with overweight or obesity, use of tirzepatide was associated with significantly greater weight loss than semaglutide. Future study is needed to understand differences in other important outcomes.</p>","PeriodicalId":14714,"journal":{"name":"JAMA Internal Medicine","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11231910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addiction Consultation Services for Opioid Use Disorder Treatment Initiation and Engagement: A Randomized Clinical Trial. 成瘾咨询服务促进阿片类药物使用障碍治疗的启动和参与:随机临床试验
IF 22.5 1区 医学
JAMA Internal Medicine Pub Date : 2024-09-01 DOI: 10.1001/jamainternmed.2024.3422
Jennifer McNeely, Scarlett S Wang, Yasna Rostam Abadi, Charles Barron, John Billings, Thaddeus Tarpey, Jasmine Fernando, Noa Appleton, Adetayo Fawole, Medha Mazumdar, Zoe M Weinstein, Roopa Kalyanaraman Marcello, Johanna Dolle, Caroline Cooke, Samira Siddiqui, Carla King
{"title":"Addiction Consultation Services for Opioid Use Disorder Treatment Initiation and Engagement: A Randomized Clinical Trial.","authors":"Jennifer McNeely, Scarlett S Wang, Yasna Rostam Abadi, Charles Barron, John Billings, Thaddeus Tarpey, Jasmine Fernando, Noa Appleton, Adetayo Fawole, Medha Mazumdar, Zoe M Weinstein, Roopa Kalyanaraman Marcello, Johanna Dolle, Caroline Cooke, Samira Siddiqui, Carla King","doi":"10.1001/jamainternmed.2024.3422","DOIUrl":"10.1001/jamainternmed.2024.3422","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Medications for opioid use disorder (MOUD) are highly effective, but only 22% of individuals in the US with opioid use disorder receive them. Hospitalization potentially provides an opportunity to initiate MOUD and link patients to ongoing treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To study the effectiveness of interprofessional hospital addiction consultation services in increasing MOUD treatment initiation and engagement.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This pragmatic stepped-wedge cluster randomized implementation and effectiveness (hybrid type 1) trial was conducted in 6 public hospitals in New York, New York, and included 2315 adults with hospitalizations identified in Medicaid claims data between October 2017 and January 2021. Data analysis was conducted in December 2023. Hospitals were randomized to an intervention start date, and outcomes were compared during treatment as usual (TAU) and intervention conditions. Bayesian analysis accounted for the clustering of patients within hospitals and open cohort nature of the study. The addiction consultation service intervention was compared with TAU using posterior probabilities of model parameters from hierarchical logistic regression models that were adjusted for age, sex, and study period. Eligible participants had an admission or discharge diagnosis of opioid use disorder or opioid poisoning/adverse effects, were hospitalized at least 1 night in a medical/surgical inpatient unit, and were not receiving MOUD before hospitalization.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interventions: &lt;/strong&gt;Hospitals implemented an addiction consultation service that provided inpatient specialty care for substance use disorders. Consultation teams comprised a medical clinician, social worker or addiction counselor, and peer counselor.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The dual primary outcomes were (1) MOUD treatment initiation during the first 14 days after hospital discharge and (2) MOUD engagement for the 30 days following initiation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of 2315 adults, 628 (27.1%) were female, and the mean (SD) age was 47.0 (12.4) years. Initiation of MOUD was 11.0% in the Consult for Addiction Treatment and Care in Hospitals (CATCH) program vs 6.7% in TAU, engagement was 7.4% vs 5.3%, respectively, and continuation for 6 months was 3.2% vs 2.4%. Patients hospitalized during CATCH had 7.96 times higher odds of initiating MOUD (log-odds ratio, 2.07; 95% credible interval, 0.51-4.00) and 6.90 times higher odds of MOUD engagement (log-odds ratio, 1.93; 95% credible interval, 0.09-4.18).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;This randomized clinical trial found that interprofessional addiction consultation services significantly increased postdischarge MOUD initiation and engagement among patients with opioid use disorder. However, the observed rates of MOUD initiation and engagement were still low; further efforts are still needed to improve hos","PeriodicalId":14714,"journal":{"name":"JAMA Internal Medicine","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141788101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The CREATE TRUST Communication Framework for Patient Messaging Services. 患者信息服务的 CREATE TRUST 通信框架。
IF 22.5 1区 医学
JAMA Internal Medicine Pub Date : 2024-09-01 DOI: 10.1001/jamainternmed.2024.2880
Matthew R Allen, Dean Schillinger, John W Ayers
{"title":"The CREATE TRUST Communication Framework for Patient Messaging Services.","authors":"Matthew R Allen, Dean Schillinger, John W Ayers","doi":"10.1001/jamainternmed.2024.2880","DOIUrl":"10.1001/jamainternmed.2024.2880","url":null,"abstract":"","PeriodicalId":14714,"journal":{"name":"JAMA Internal Medicine","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141788109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信